AR082004A1 - Compuestos de fusion de piridina - Google Patents
Compuestos de fusion de piridinaInfo
- Publication number
- AR082004A1 AR082004A1 ARP110102108A ARP110102108A AR082004A1 AR 082004 A1 AR082004 A1 AR 082004A1 AR P110102108 A ARP110102108 A AR P110102108A AR P110102108 A ARP110102108 A AR P110102108A AR 082004 A1 AR082004 A1 AR 082004A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- heterocycloalkyl
- haloalkoxy
- haloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
La presente se refiere a moduladores duales de los receptores de la 5-HT2A y de la D3. La presente se refiere además a la obtención de los compuestos de la fórmula (1), a composiciones farmacéuticas que los contienen y a su utilización como medicamentos.Reivindicación 1: Un compuesto de la fórmula (1) en la que: X es O ó S; Y es -C(O)- o -S(O)2-; A es un enlace sencillo o un doble enlace, con la condición de que si X es S, entonces A sea un doble enlace; R1 es hidrógeno, alquilo C1-7, haloalquilo C1-7, alquenilo C2-7, alquinilo C2-7, cicloalquilo, heterocicloalquilo, arilo, arilo fusionado con un heterocicloalquilo, heteroarilo, -N(R6)2, dichos alquilo C1-7, haloalquilo C1-7, alquenilo C2-7, alquinilo C2-7 están opcionalmente sustituidos de una a tres veces por sustituyentes elegidos con independencia entre el grupo formado por ciano, cicloalquilo, heterocicloalquilo, arilo, arilo fusionado con un heterocicloalquilo, heteroarilo, -C(O)N(R6)2, -N(R6)2, -NH(CO)-alquilo C1-7, hidroxi, alcoxi C1-7, haloalcoxi C1-7, oxo y -S(O)2R7 y dichos cicloalquilo, heterocicloalquilo, arilo, arilo fusionado con un heterocicloalquilo y heteroarilo están opcionalmente sustituidos de una a tres veces por R4 independientes; R2, R3 son con independencia hidrógeno, halógeno, alquilo C1-7, haloalquilo C1-7, hidroxi, alcoxi C1-7 o haloalcoxi C1-7; R4 es halógeno, ciano, alquilo C1-7, haloalquilo C1-7, cicloalquilo, heterocicloalquilo, arilo, arilo fusionado con un heterocicloalquilo, heteroarilo, -C(O)N(R6)2, -N(R6)2, -NH(CO)-alquilo C1-7, hidroxi, alcoxi C1-7, haloalcoxi C1-7, oxo, -S(O)2R7 o alquilo C1-7 sustituido de una a tres veces por sustituyentes elegidos con independencia entre el grupo formado por ciano, hidroxi, alcoxi C1-7 y haloalcoxi C1-7, dichos cicloalquilo, heterocicloalquilo, arilo y heteroarilo están opcionalmente sustituidos de una a tres veces por R5 independientes; R5 es halógeno, ciano, alquilo C1-7, haloalquilo C1-7, hidroxi, alcoxi C1-7, haloalcoxi C1-7 u oxo; R6 es hidrógeno o alquilo C1-7; R7 es hidrógeno, alquilo C1-7 o arilo, dicho arilo está opcionalmente sustituido de una a tres veces por R5 independientes; y las sales y ésteres farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10166652 | 2010-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082004A1 true AR082004A1 (es) | 2012-11-07 |
Family
ID=44260006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102108A AR082004A1 (es) | 2010-06-21 | 2011-06-17 | Compuestos de fusion de piridina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8586579B2 (es) |
| EP (1) | EP2582705B1 (es) |
| JP (1) | JP2013529610A (es) |
| KR (1) | KR20130120997A (es) |
| CN (1) | CN102947310B (es) |
| AR (1) | AR082004A1 (es) |
| BR (1) | BR112012032748A2 (es) |
| CA (1) | CA2792966A1 (es) |
| ES (1) | ES2508170T3 (es) |
| MX (1) | MX2012013637A (es) |
| RU (1) | RU2012157404A (es) |
| TW (1) | TW201204737A (es) |
| WO (1) | WO2011161009A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000032987A (ja) * | 1998-07-16 | 2000-02-02 | Dai Ichi Seiyaku Co Ltd | Ｄｎａ |
| US8470828B2 (en) * | 2010-07-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US8877778B2 (en) | 2010-12-15 | 2014-11-04 | Hoffmann-La Roche Inc. | Benzofurane compounds |
| US8722683B2 (en) * | 2011-02-17 | 2014-05-13 | Hoffmann La-Roche Inc. | Benzodioxole piperazine compounds |
| US8921397B2 (en) | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| AR095264A1 (es) | 2013-03-15 | 2015-09-30 | Abbvie Deutschland | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| CN104140421B (zh) * | 2013-05-08 | 2017-04-05 | 上海医药工业研究院 | 苯并异噻唑类化合物及在制备抗精神***症药物中的应用 |
| EP3495363B1 (en) | 2016-07-28 | 2023-08-23 | Shionogi & Co., Ltd | Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect |
| CN111801330B (zh) | 2018-01-26 | 2024-04-05 | 盐野义制药株式会社 | 具有多巴胺d3受体拮抗作用的稠环化合物 |
| WO2019146740A1 (ja) | 2018-01-26 | 2019-08-01 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する環式化合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0500170A3 (en) * | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
| BRPI0707960A2 (pt) | 2006-02-17 | 2011-05-10 | Hoffmann La Roche | derivados de benzoil-piperidina como moduladores de 5ht2/d3, medicamento e uso dos mesmos |
| EP1870405A1 (en) | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
| CA2694057A1 (en) | 2007-08-09 | 2009-02-12 | F. Hoffmann-La Roche Ag | Benzoyl-piperidine derivatives as dual modulators of the 5-ht2a and d3 receptors |
| AU2009294695B2 (en) | 2008-09-22 | 2012-09-13 | F. Hoffmann-La Roche Ag | Piperazine D3 and 5-HT2a receptor modulators |
| JP2012502948A (ja) | 2008-09-23 | 2012-02-02 | エフ．ホフマン−ラ ロシュ アーゲー | ドーパミンｄ３受容体の調節剤として有用なイソオキサゾロ［４，５］ピリジン−３−イル−ピペラジン誘導体 |
| JP2012502947A (ja) | 2008-09-23 | 2012-02-02 | エフ．ホフマン−ラ ロシュ アーゲー | ドーパミンＤ３受容体の調節剤として有用なベンゾ［ｄ］イソオキサゾール−３−イル−ピペラジン誘導体 |
| US8470828B2 (en) * | 2010-07-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
-
2011
- 2011-06-16 US US13/161,548 patent/US8586579B2/en not_active Expired - Fee Related
- 2011-06-17 MX MX2012013637A patent/MX2012013637A/es active IP Right Grant
- 2011-06-17 CA CA2792966A patent/CA2792966A1/en not_active Abandoned
- 2011-06-17 JP JP2013515819A patent/JP2013529610A/ja active Pending
- 2011-06-17 WO PCT/EP2011/060080 patent/WO2011161009A1/en active Application Filing
- 2011-06-17 BR BR112012032748A patent/BR112012032748A2/pt not_active IP Right Cessation
- 2011-06-17 ES ES11727156.9T patent/ES2508170T3/es active Active
- 2011-06-17 KR KR1020127033220A patent/KR20130120997A/ko not_active Application Discontinuation
- 2011-06-17 AR ARP110102108A patent/AR082004A1/es unknown
- 2011-06-17 TW TW100121273A patent/TW201204737A/zh unknown
- 2011-06-17 CN CN201180030998.4A patent/CN102947310B/zh not_active Expired - Fee Related
- 2011-06-17 RU RU2012157404/04A patent/RU2012157404A/ru not_active Application Discontinuation
- 2011-06-17 EP EP11727156.9A patent/EP2582705B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| CA2792966A1 (en) | 2011-12-29 |
| JP2013529610A (ja) | 2013-07-22 |
| TW201204737A (en) | 2012-02-01 |
| CN102947310B (zh) | 2015-11-25 |
| KR20130120997A (ko) | 2013-11-05 |
| EP2582705A1 (en) | 2013-04-24 |
| RU2012157404A (ru) | 2014-07-27 |
| US8586579B2 (en) | 2013-11-19 |
| ES2508170T3 (es) | 2014-10-16 |
| BR112012032748A2 (pt) | 2016-11-08 |
| WO2011161009A1 (en) | 2011-12-29 |
| US20110313151A1 (en) | 2011-12-22 |
| MX2012013637A (es) | 2013-01-24 |
| CN102947310A (zh) | 2013-02-27 |
| EP2582705B1 (en) | 2014-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082004A1 (es) | Compuestos de fusion de piridina | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| AR081649A1 (es) | Compuestos heteroarilo nitrogenados | |
| AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR093184A1 (es) | Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR073136A1 (es) | Compuestos de pirrol | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| ECSP088731A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| AR082889A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| CO6400145A2 (es) | Derivados de 2-piridin-2-il pirazol-3(2h) -ona, su preparción y su aplicación terapeútica | |
| AR069814A1 (es) | Derivados de 4 amino-pirimidina, proceso de preparacion y composiciones farmaceuticas que los contienen | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
| NI201000134A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| CO6251363A2 (es) | Derivados de indol-2-ona disustituidos en 3 su preparacion y su aplicacion en terapeutica | |
| AR085236A1 (es) | Compuestos de benzodioxol-piperazina como moduladores de los receptores 5-hty d | |
| ES2587745T3 (es) | Derivados de imidazo[2,1]tiazol-3-ona útiles como agentes de diagnóstico para la enfermedad de Alzheimer | |
| AR046228A1 (es) | Derivados de indol como activadores ppar, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de medicamentos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |